Celgene Stock EBITDA
Celgene fundamentals help investors to digest information that contributes to Celgene's financial success or failures. It also enables traders to predict the movement of Celgene Stock. The fundamental analysis module provides a way to measure Celgene's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Celgene stock.
Celgene |
Celgene Company EBITDA Analysis
Celgene's EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Current Celgene EBITDA | 8.42 B |
Most of Celgene's fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Celgene is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
CompetitionAccording to the company disclosure, Celgene reported earnings before interest,tax, depreciation and amortization of 8.42 B. This is much higher than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—General industry. The ebitda for all United States stocks is 115.98% lower than that of the firm.
Celgene EBITDA Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Celgene's direct or indirect competition against its EBITDA to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Celgene could also be used in its relative valuation, which is a method of valuing Celgene by comparing valuation metrics of similar companies.Celgene is currently under evaluation in ebitda category among its peers.
Celgene Fundamentals
Return On Equity | 1.0E-4 | |||
Return On Asset | 0.14 | |||
Profit Margin | 0.30 % | |||
Operating Margin | 51.47 % | |||
Current Valuation | 85.34 B | |||
Shares Outstanding | 708.74 M | |||
Shares Owned By Insiders | 0.22 % | |||
Shares Owned By Institutions | 77.62 % | |||
Number Of Shares Shorted | 12.95 M | |||
Price To Earning | 13.31 X | |||
Price To Book | 7.45 X | |||
Price To Sales | 4.54 X | |||
Revenue | 16.35 B | |||
Gross Profit | 14.06 B | |||
EBITDA | 8.42 B | |||
Net Income | 5.27 B | |||
Cash And Equivalents | 9.32 B | |||
Cash Per Share | 13.15 X | |||
Total Debt | 20.1 B | |||
Debt To Equity | 199.90 % | |||
Current Ratio | 3.44 X | |||
Book Value Per Share | 9.22 X | |||
Cash Flow From Operations | 6.35 B | |||
Short Ratio | 3.45 X | |||
Earnings Per Share | 7.32 X | |||
Price To Earnings To Growth | 0.67 X | |||
Number Of Employees | 8.85 K | |||
Beta | 1.41 | |||
Market Capitalization | 77.04 B | |||
Total Asset | 1.11 B | |||
Retained Earnings | 21.79 B | |||
Working Capital | 708.47 M | |||
Current Asset | 849.88 M | |||
Current Liabilities | 141.41 M | |||
Z Score | 69.79 |
Currently Active Assets on Macroaxis
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.
Other Consideration for investing in Celgene Stock
If you are still planning to invest in Celgene check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Celgene's history and understand the potential risks before investing.
Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
CEOs Directory Screen CEOs from public companies around the world | |
Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA |